Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ.

Neurotherapeutics. 2017 Jan;14(1):35-53. doi: 10.1007/s13311-016-0481-z. Review.

PMID:
27738903
2.

Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.

Declercq LD, Vandenberghe R, Van Laere K, Verbruggen A, Bormans G.

Front Pharmacol. 2016 Mar 31;7:88. doi: 10.3389/fphar.2016.00088. eCollection 2016. Review.

3.

Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study.

Clark LR, Racine AM, Koscik RL, Okonkwo OC, Engelman CD, Carlsson CM, Asthana S, Bendlin BB, Chappell R, Nicholas CR, Rowley HA, Oh JM, Hermann BP, Sager MA, Christian BT, Johnson SC.

Alzheimers Dement. 2016 Jul;12(7):805-14. doi: 10.1016/j.jalz.2015.12.009. Epub 2016 Jan 21.

4.

Hippocampal Injections of Oligomeric Amyloid β-peptide (1-42) Induce Selective Working Memory Deficits and Long-lasting Alterations of ERK Signaling Pathway.

Faucher P, Mons N, Micheau J, Louis C, Beracochea DJ.

Front Aging Neurosci. 2016 Jan 11;7:245. doi: 10.3389/fnagi.2015.00245. eCollection 2015.

5.

Exploring the effects of coexisting amyloid in subcortical vascular cognitive impairment.

Dao E, Hsiung GY, Sossi V, Jacova C, Tam R, Dinelle K, Best JR, Liu-Ambrose T.

BMC Neurol. 2015 Oct 12;15:197. doi: 10.1186/s12883-015-0459-1. Erratum in: BMC Neurol. 2016;16(1):157.

6.

Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months.

Thai C, Lim YY, Villemagne VL, Laws SM, Ames D, Ellis KA, Rainey-Smith SR, Martins RN, Masters CL, Rowe CC, Maruff P; Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group.

PLoS One. 2015 Oct 2;10(10):e0139082. doi: 10.1371/journal.pone.0139082. eCollection 2015.

7.

Alzheimer Lesions in the Autopsied Brains of People 30 to 50 Years of Age.

Pletnikova O, Rudow GL, Hyde TM, Kleinman JE, Ali SZ, Bharadwaj R, Gangadeen S, Crain BJ, Fowler DR, Rubio AI, Troncoso JC.

Cogn Behav Neurol. 2015 Sep;28(3):144-52. doi: 10.1097/WNN.0000000000000071.

8.

Brain Amyloid Deposition and Longitudinal Cognitive Decline in Nondemented Older Subjects: Results from a Multi-Ethnic Population.

Gu Y, Razlighi QR, Zahodne LB, Janicki SC, Ichise M, Manly JJ, Devanand DP, Brickman AM, Schupf N, Mayeux R, Stern Y.

PLoS One. 2015 Jul 29;10(7):e0123743. doi: 10.1371/journal.pone.0123743. eCollection 2015.

9.

Interactive effects of vascular risk burden and advanced age on cerebral blood flow.

Bangen KJ, Nation DA, Clark LR, Harmell AL, Wierenga CE, Dev SI, Delano-Wood L, Zlatar ZZ, Salmon DP, Liu TT, Bondi MW.

Front Aging Neurosci. 2014 Jul 7;6:159. doi: 10.3389/fnagi.2014.00159. eCollection 2014.

10.

Repair of oxidative DNA damage, cell-cycle regulation and neuronal death may influence the clinical manifestation of Alzheimer's disease.

Silva AR, Santos AC, Farfel JM, Grinberg LT, Ferretti RE, Campos AH, Cunha IW, Begnami MD, Rocha RM, Carraro DM, de Bragança Pereira CA, Jacob-Filho W, Brentani H.

PLoS One. 2014 Jun 17;9(6):e99897. doi: 10.1371/journal.pone.0099897. eCollection 2014.

11.

Early detection of Alzheimer's disease using PiB and FDG PET.

Cohen AD, Klunk WE.

Neurobiol Dis. 2014 Dec;72 Pt A:117-22. doi: 10.1016/j.nbd.2014.05.001. Epub 2014 May 10. Review.

12.

Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.

Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Joshi AD, Lu M, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ; AV45-A11 Study Group; AV45-A11 Study Group.

Mol Psychiatry. 2014 Sep;19(9):1044-51. doi: 10.1038/mp.2014.9. Epub 2014 Mar 11.

13.

Cerebral amyloid PET imaging in Alzheimer's disease.

Jack CR Jr, Barrio JR, Kepe V.

Acta Neuropathol. 2013 Nov;126(5):643-57. doi: 10.1007/s00401-013-1185-7. Epub 2013 Oct 8. Review.

14.

Reference region automatic extraction in dynamic [(11)C]PIB.

Ikoma Y, Edison P, Ramlackhansingh A, Brooks DJ, Turkheimer FE.

J Cereb Blood Flow Metab. 2013 Nov;33(11):1725-31. doi: 10.1038/jcbfm.2013.133. Epub 2013 Aug 7.

15.

Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden.

Yotter RA, Doshi J, Clark V, Sojkova J, Zhou Y, Wong DF, Ferrucci L, Resnick SM, Davatzikos C.

Neurobiol Aging. 2013 Dec;34(12):2835-42. doi: 10.1016/j.neurobiolaging.2013.05.030. Epub 2013 Jul 13.

16.

Pattern and predictability in memory formation: from molecular mechanisms to clinical relevance.

Philips GT, Kopec AM, Carew TJ.

Neurobiol Learn Mem. 2013 Oct;105:117-24. doi: 10.1016/j.nlm.2013.05.003. Epub 2013 May 28. Review.

17.

TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies.

Arnold SJ, Dugger BN, Beach TG.

Acta Neuropathol. 2013 Jul;126(1):51-7. doi: 10.1007/s00401-013-1110-0. Epub 2013 Apr 20.

18.

Neuropathological approaches to cerebral aging and neuroplasticity.

Jellinger KA, Attems J.

Dialogues Clin Neurosci. 2013 Mar;15(1):29-43. Review.

19.

The neuropsychology of normal aging and preclinical Alzheimer's disease.

Caselli RJ, Locke DE, Dueck AC, Knopman DS, Woodruff BK, Hoffman-Snyder C, Rademakers R, Fleisher AS, Reiman EM.

Alzheimers Dement. 2014 Jan;10(1):84-92. doi: 10.1016/j.jalz.2013.01.004. Epub 2013 Mar 26.

20.

Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia.

Snitz BE, Weissfeld LA, Lopez OL, Kuller LH, Saxton J, Singhabahu DM, Klunk WE, Mathis CA, Price JC, Ives DG, Cohen AD, McDade E, Dekosky ST.

Neurology. 2013 Apr 9;80(15):1378-84. doi: 10.1212/WNL.0b013e31828c2fc8. Epub 2013 Mar 20.

Supplemental Content

Support Center